XDx, Inc. Forms Deal with LabCorp

BRISBANE, Calif.--(BUSINESS WIRE)--XDx, Inc., a molecular diagnostics company focused on noninvasive gene expression tests to monitor immune-mediated conditions, today announced that it has entered into a multi-year agreement with Laboratory Corporation of America Holdings (LabCorp; NYSE:LH) to provide heart transplant patients eligible for XDx’s AlloMap® test with the convenience of having their blood drawn at participating LabCorp sites across the United States.